Login to Your Account

Eyevensys adds $10M in series A funding for plasmid-based ocular gene therapy program

By Cormac Sheridan
Staff Writer

Thursday, September 15, 2016

DUBLIN – Eyevensys SAS extended its series A funding round with an injection of €1.5 million (US$ 1.7 million) from Pontifax Venture Capital, taking the total raise to €9 million. The Paris-based company is pioneering gene delivery to the eye using electroporation or, in its own parlance, “electro-transfection.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription